Dompé U.S. Agrees to Pay $32M to Resolve False Claims Act Liability Relating to Self-Disclosure of Patient Kickbacks
Dompé U.S. Inc. (Dompé), based in California, has agreed to pay $32 million to resolve allegations that, between 2018 and 2021, it paid Medicare beneficiary co-pays through two patient assistance foundations to induce the purchase of its drug, Oxervate, in violation of the Anti-Kickback Statute and the False Claims Act.
Contenu original affiche; la traduction localisee n'est pas encore disponible.
Ce qui s'est passé
Dompé U.S. Inc. (Dompé), based in California, has agreed to pay $32 million to resolve allegations that, between 2018 and 2021, it paid Medicare beneficiary co-pays through two patient assistance foundations to induce the purchase of its drug, Oxervate, in violation of the Anti-Kickback Statute and the False Claims Act.
Pourquoi c'est important
The development may change operating conditions or market expectations around Regulation. Further confirmation and measurable outcomes matter.
Entités concernées
Voir les preuves
1 articles · 1 publication d'origine · 1 independantes
- U.S. Department of JusticeSource primaire · Confirme · EN · 100%Dompé U.S. Agrees to Pay $32M to Resolve False Claims Act Liability Relating to Self-Disclosure of Patient Kickbacks ↗
Affirmations
- Dompé U.S. Agrees to Pay $32M to Resolve False Claims Act Liability Relating to Self-Disclosure of Patient Kickbacks Observé
Divergences
Aucune divergence importante détectée dans les preuves disponibles.
Chronologie
- Premier signalement
Mouvement de marché suivant l'événement
La réaction du marché n'est pas encore disponible pour cet actif et cette fenêtre.